ONO PHARMA Announces Enrollment is Complete for the First Arm of the PROSPECT Study of Tirabrutinib in U.S. Patients with Relapsed or Refractory PCNSL ...Middle East

Primary central nervous system lymphoma (PCNSL) is a rare and aggressive lymphoma with no approved treatment in the U.S.1 OSAKA, Japan, March 25, 2024 /PRNewswire/ -- ONO Pharmaceuticals, Co., Ltd. today announced it has completed target patient enrollment of the first arm (Part A) of the...

Hence then, the article about ono pharma announces enrollment is complete for the first arm of the prospect study of tirabrutinib in u s patients with relapsed or refractory pcnsl was published today ( Monday 25/03/2024 - 12:12 PM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( ONO PHARMA Announces Enrollment is Complete for the First Arm of the PROSPECT Study of Tirabrutinib in U.S. Patients with Relapsed or Refractory PCNSL )

Also on site :

• Brandon Sanderson’s Literary Fantasy Universe ‘Cosmere’ Picked Up by Apple TV (Exclusive)
• BREAKING: Andrew Walker to Star in Hallmark's Newest History-Making Crossover Movie Event
• Bad Bunny's Super Bowl Guest List Could Include Other Major Stars